James Ortman, MD
Internal Medicine · Omaha, NENPI 1154423085
Payments from drug & device makers
Across 106 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$230
- Pfizer$215
- Novartis$175
- Amgen$175
- Novo Nordisk$157
- AbbVie$109
- plus $655 from 21 others
What the payments were for
- Food & beverage$1,717100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 15 | $230 |
| Pfizer | 13 | $215 |
| Novartis | 12 | $175 |
| Amgen | 12 | $175 |
| Novo Nordisk | 10 | $157 |
| AbbVie | 7 | $109 |
| Xeris Pharmaceuticals, Inc. | 5 | $84 |
| Sanofi-aventis U.S. LLC | 4 | $80 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $38 |
| Bayer | 2 | $35 |
| Astellas Pharma US Inc | 2 | $31 |
| Merck | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Amphastar Pharmaceuticals, Inc. | 1 | $24 |
| Abbott | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Biogen | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$1,717 in reported general payments places this provider in the 80th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 388 | $213,807 |
| OzempicSemaglutide | 68 | $80,408 |
| JardianceEmpagliflozin | 52 | $49,194 |
| MyrbetriqMirabegron | 103 | $33,400 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 16 | $32,984 |
| XareltoRivaroxaban | 51 | $32,822 |
| FarxigaDapagliflozin Propanediol | 25 | $27,996 |
| Repatha SureclickEvolocumab | 29 | $19,635 |
| TrulicityDulaglutide | 15 | $18,794 |
| EntrestoSacubitril/Valsartan | 24 | $18,353 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,502 |
| Atorvastatin Calcium | 612 | $8,153 |
| Pantoprazole Sodium | 190 | $5,759 |
| Metoprolol Succinate | 304 | $4,731 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $3,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $215 | $217,140401 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $157 | $113,39384 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $33,400103 claims |
| Johnson & JohnsonXarelto | $12 | $32,82251 claims |
| Lilly USA, LLCTrulicity, Humulin 70-30 | $230 | $20,29529 claims |
| NovartisEntresto | $175 | $18,35324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Omaha
- Michael DunnOmaha$7.9M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- David CrockettOmaha$821K
- Bryant EnglandOmaha$637K
- Adam BurdorfOmaha$313K
- Brian BoerOmaha$142K
- David JasperOmaha$128K
- Andrew RorieOmaha$61K
- Mohamed AhmedOmaha$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.